aacs Antibody

What is AACS and why is it significant in metabolic research?

AACS (Acetoacetyl-CoA Synthetase) is a 75 kDa enzyme that plays a crucial role in ketone body metabolism. It functions primarily by converting acetoacetate to acetoacetyl-CoA in the cytosol and serves as a key ketone body-utilizing enzyme responsible for the synthesis of cholesterol and fatty acids . This enzyme represents an important target for investigating lipid metabolism pathways, particularly in conditions where ketone utilization is altered.

AACS research is valuable for studying:

• Cholesterol biosynthesis regulation

• Lipid metabolism disorders

• Ketone body utilization in different tissues

• Metabolic adaptations during fasting or ketogenic diets

What are the primary applications of AACS antibodies in research?

Based on available validation data, AACS antibodies have demonstrated utility in several experimental techniques:

The choice of application should be guided by published validation data for the specific antibody clone being considered.

How should researchers interpret AACS antibody specificity data?

When evaluating AACS antibody specificity, researchers should consider:

• Target epitope location: Different antibodies target distinct regions of the protein (e.g., AA 539-573 C-Term, AA 400-600, or AA 182-228)

• Cross-reactivity profile: Some antibodies show reactivity with multiple species (Human, Rat, Mouse) while others are species-specific

• Validation methods used: Comprehensive validation includes positive controls (overexpression systems), negative controls (knockdown/knockout), and detection of the expected molecular weight band

• Specific versus non-specific binding: Evaluate background signal in control samples

A properly validated antibody should demonstrate a clean band at the expected molecular weight (~75 kDa for AACS) with minimal non-specific binding.

What are the optimal protocols for using AACS antibodies in Western blotting?

When performing Western blotting with AACS antibodies, the following protocol considerations are recommended:

• Sample preparation:

  • Use RIPA or NP-40 buffer with protease inhibitors

  • Load 10-20 μg of total protein per lane

  • Include HEK-293 cell lysate as a positive control

• Gel and transfer conditions:

  • 8-10% polyacrylamide gels are suitable for resolving the 75 kDa AACS protein

  • Wet transfer at 100V for 1 hour or 30V overnight

• Antibody incubation:

  • Primary antibody: 1:500 dilution (optimal range 1:200-1:1000)

  • Incubate overnight at 4°C in 5% BSA or milk blocking solution

  • Secondary antibody: HRP-conjugated anti-rabbit IgG at 1:2000-1:50000

• Detection system:

  • Enhanced chemiluminescence (ECL) is typically sufficient

  • Expected band: ~75 kDa

• Troubleshooting:

  • Multiple bands may indicate degradation products or post-translational modifications

  • Absence of signal might require increased antibody concentration or extended exposure times

How should immunoprecipitation protocols be optimized for AACS studies?

For successful immunoprecipitation of AACS:

• Starting material:

  • Use 500-1000 μg of total protein from cell lysate

  • Prepare lysates in non-denaturing buffers (e.g., NP-40 or Triton X-100 buffer)

• Antibody binding:

  • Use 2-5 μg of AACS antibody per 500 μg of lysate

  • Incubate overnight at 4°C with gentle rotation

• Capture method:

  • Protein A/G beads for rabbit polyclonal antibodies

  • Pre-clear lysates to reduce non-specific binding

  • Include appropriate negative controls (non-immune IgG)

• Washing and elution:

  • Perform at least 3-5 washes with decreasing salt concentrations

  • Elute proteins using SDS sample buffer at 95°C for 5 minutes

• Verification:

  • Analyze by Western blot using a different AACS antibody (if available) to confirm specificity

  • Include input (10 μg), IgG control, and IP sample on the same blot

This method has been validated for human HEK-293 cells and may require optimization for other cell types or tissues.

What considerations are important when using AACS antibodies for immunohistochemistry?

When performing immunohistochemistry with AACS antibodies:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) tissues have been validated

  • Section thickness: 4-6 μm recommended

• Antigen retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Pressure cooker or microwave methods (20 minutes)

• Blocking and antibody incubation:

  • Block with 5-10% normal serum from secondary antibody host species

  • Primary antibody dilution: 1:100 for paraffin sections

  • Incubate overnight at 4°C or 1-2 hours at room temperature

• Detection system:

  • HRP-polymer or biotin-streptavidin systems are suitable

  • DAB (3,3'-diaminobenzidine) for chromogenic detection

  • Include negative controls (primary antibody omission, isotype control)

• Result interpretation:

  • AACS shows cytoplasmic localization

  • Validated in human kidney tissue

  • Compare staining pattern with available literature

How can AACS antibodies be used to investigate metabolic pathway interactions?

AACS antibodies can facilitate advanced studies of metabolic pathway interactions through:

• Co-immunoprecipitation assays:

  • Use AACS antibodies to pull down protein complexes

  • Identify novel interaction partners by mass spectrometry

  • Validate interactions with reciprocal co-IP experiments

• Proximity ligation assays (PLA):

  • Detect in situ protein-protein interactions with AACS

  • Requires two primary antibodies against different proteins

  • Provides spatial information about interaction events

• ChIP-seq applications:

  • If AACS has transcription factor or chromatin-associated functions

  • Requires validation of antibody specificity for ChIP applications

• Tissue-specific expression profiling:

  • Compare AACS expression across different metabolic states

  • Correlate with physiological parameters or disease markers

These approaches can reveal how AACS interacts with other enzymes involved in lipid metabolism and ketone body utilization pathways.

What considerations are important when studying AACS in relation to disease models?

When investigating AACS in disease contexts:

• Expression level analysis:

  • Quantify AACS levels in normal versus disease tissues

  • Use multiple detection methods (WB, IHC, qPCR) for comprehensive assessment

• Activity correlation studies:

  • Pair antibody-based detection with enzymatic activity assays

  • Determine if protein abundance correlates with functional activity

• Post-translational modification analysis:

  • Use phospho-specific or other PTM-specific antibodies if available

  • Consider how modifications affect enzyme function

• Genetic modification approaches:

  • Validate antibody specificity in knockout/knockdown models

  • Use these models to confirm pathological relevance

• Therapeutic intervention studies:

  • Monitor AACS levels during drug treatment

  • Assess whether AACS could serve as a biomarker for treatment response

Understanding how AACS expression and function change in disease states may reveal new therapeutic targets or diagnostic approaches.

How do post-translational modifications of AACS affect antibody recognition?

Post-translational modifications (PTMs) can significantly impact antibody binding to AACS:

• Epitope accessibility:

  • Phosphorylation, acetylation, or other modifications may alter protein conformation

  • Modifications within the antibody epitope region can block antibody binding

  • C-terminal antibodies (AA 539-573) may be affected by C-terminal modifications

• Experimental considerations:

  • Use phosphatase treatment to assess phosphorylation effects on antibody binding

  • Compare reducing versus non-reducing conditions for disulfide bond influences

  • Consider cross-reactivity with modified forms when interpreting results

• Multiple band patterns:

  • Western blots showing additional bands may represent modified AACS forms

  • Verify with mass spectrometry or PTM-specific antibodies

  • Document migration patterns for different modifications

• Strategy for comprehensive analysis:

  • Use multiple antibodies targeting different epitopes

  • Combine with mass spectrometry to identify specific modification sites

  • Correlate modifications with functional changes in enzyme activity

Research on AACS PTMs remains limited, representing an opportunity for novel discoveries in metabolic regulation.

What are common issues when working with AACS antibodies and how can they be addressed?

How should researchers validate new AACS antibody lots?

When validating new antibody lots, researchers should:

• Compare with previous lots:

  • Run side-by-side Western blots with old and new lots

  • Use the same positive control samples (e.g., HEK-293 cells)

  • Compare band intensity, pattern, and background

• Perform basic validation assays:

  • Western blot to confirm expected molecular weight (~75 kDa)

  • IHC on tissues with known expression patterns

  • IP to verify antibody's ability to pull down the target

• Document lot-specific optimization:

  • Determine optimal dilutions for each application

  • Record any differences in protocol requirements

  • Maintain detailed records for reproducibility

• Advanced validation (when possible):

  • Test on overexpression systems

  • Validate on knockout/knockdown samples

  • Perform peptide competition assays

Thorough validation prevents experimental artifacts and ensures data reliability.

What are the technical differences between monoclonal and polyclonal AACS antibodies?

Most commercially available AACS antibodies are polyclonal, offering advantages in detection sensitivity at the cost of potential increased background.

How can modern antibody engineering improve AACS research tools?

Emerging antibody technologies that could enhance AACS research include:

• Recombinant antibody development:

  • Single-chain variable fragments (scFvs) for improved tissue penetration

  • Phage display selection for higher specificity

  • Genetically encoded intrabodies for live-cell imaging

• Site-specific conjugation:

  • Precisely controlled fluorophore attachment for quantitative imaging

  • Enzyme conjugates for proximity-based detection

  • Nanoparticle conjugation for multiplexed detection

• Bispecific antibodies:

  • Simultaneous detection of AACS and interacting partners

  • Improved co-localization studies

  • Enhanced pull-down efficiency for complex isolation

• Alpaca-derived nanobodies:

  • Smaller size for accessing hidden epitopes

  • Improved stability for harsh experimental conditions

  • Potential for intracellular expression

These techniques could address current limitations in studying AACS's dynamic interactions and subcellular localization.

What methodological approaches can improve reproducibility in AACS antibody-based research?

To enhance reproducibility when working with AACS antibodies:

• Standardized validation framework:

  • Implement minimum validation criteria before experimental use

  • Document validation results in publications

  • Share validation data through antibody validation repositories

• Orthogonal detection methods:

  • Confirm findings using multiple antibody-independent techniques

  • Combine antibody detection with mass spectrometry

  • Correlate protein and mRNA expression data

• Transparent reporting:

  • Document complete antibody information (catalog number, lot, dilution)

  • Report all optimization steps and controls

  • Share detailed protocols through protocol repositories

• Reference standards:

  • Use recombinant AACS protein as a standard

  • Implement common positive control samples across labs

  • Develop consensus on interpretation of AACS detection patterns

Implementing these approaches can significantly improve data reliability and cross-laboratory reproducibility.